# Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

> **NCT00783692** · PHASE3 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 1116 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** vedolizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00783692
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2012-03
- **Final completion:** 2012-05
- **Target enrollment:** 1116 (ACTUAL)
- **Last updated:** 2014-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00783692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00783692, "Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00783692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*